Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GNI Group
Tokyo, Tokyo, Japan
- Ownership
- Public · 2160.T
- Development stage
- Other
01
Overview
GNI Group commercialized pirfenidone (Etuary) for idiopathic pulmonary fibrosis in China and partnered for ex-China sales; advanced F351 for liver fibrosis approaching NDA; Cullgen subsidiary developing protein-degradation cancer therapeutics, with ongoing clinical progress and merger transactions.
- Therapeutic areas
- OncologyPulmonologyImmunologyGastroenterology
- Modalities
- Small moleculeProteinPlatform: targeted protein-degradation
- Industry
- Biotech
02
Partnerships
AFT Pharmaceuticals (commercialization outside China for pirfenidone/Etuary)Co-development and licensing partnerships (not all partners disclosed)
Beyond the preview
Go deeper on GNI Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNI Group.